| Old Articles: <Older 1191-1200 Newer> |
|---|
 |
Bio-IT World
May 19, 2004
Branca, Hoffer & Nambiar |
Keeping an Even Keel Bland first quarter was punctuated by HGS mini-drama: Biotech guru Steven Burrill hailed the first quarter of 2004 as biotech's best funding quarter in the industry's 30-year history. But it was also a strange one.   |
Bio-IT World
May 19, 2004 |
Special Delivery TAT tagging has aroused keen interest in biotech. |
Bio-IT World
May 19, 2004
Julia Boguslavsky |
Is Microfluidics Equipped for HTS? As microfluidics technologies mature and increase in throughput, they are starting to offer a highly accurate, flexible, and economical alternative to conventional high-throughput screening (HTS) platforms. |
Bio-IT World
May 19, 2004
John Russell |
Seeing the Forest and the Trees A tiny clearing in the fog of systems biology. |
BusinessWeek
May 31, 2004
Gene G. Marcial |
Seeking Sepracor? Sepracor is takeover bait because it is just what Big Pharma wants: diversified drugs and the newly approved sleep-disorder medication with blockbuster potential, Estorra. |
The Motley Fool
May 20, 2004
W.D. Crotty |
$1 Billion Pharmion? The specialty drug company's stock soars on the FDA's approval of a drug that treats a blood condition. |
The Motley Fool
May 20, 2004
Tom Taulli |
Cardinal Rules of M&A Cardinal Health is upbeat on its latest acquisition, but needs bigger deals to push growth. |
The Motley Fool
May 19, 2004
Roger Nusbaum |
Gilead Shines This biotech company looks strong because investors can relate to its products. |
The Motley Fool
May 19, 2004
W.D. Crotty |
Big Loser Looks Good It's the day's big percentage loser, but the future looks good for Synovis Life Technologies. |
The Motley Fool
May 19, 2004
Richard Gibbons |
Orthodontic Centers' Surgery Orthodontic's slashed earnings are actually positive for investors. |
| <Older 1191-1200 Newer> Return to current articles. |
